Circulating Tumour DNA Biomarkers in Savolitinib-Treated Patients with Non-Small Cell Lung Cancer Harbouring MET Exon 14 Skipping Alterations: a Post Hoc Analysis of a Pivotal Phase 2 Study.
Yongfeng Yu,Yongxin Ren,Jian Fang,Lejie Cao,Zongan Liang,Qisen Guo,Sen Han,Zimei Ji,Ye Wang,Yulan Sun,Yuan Chen,Xingya Li,Hua Xu,Jianying Zhou,Liyan Jiang,Ying Cheng,Zhigang Han,Jianhua Shi,Gongyan Chen,Rui Ma,Yun Fan,Sanyuan Sun,Longxian Jiao,Xiaoyun Jia,Linfang Wang,Puhan Lu,Qian Xu,Xian Luo,Weiguo Su,Shun Lu
DOI: https://doi.org/10.1177/17588359221133546
2022-01-01
Therapeutic Advances in Medical Oncology
Abstract:Background:Savolitinib, a selective MET inhibitor, showed efficacy in patients with non-small cell lung cancer (NSCLC), including pulmonary sarcomatoid carcinoma (PSC), harbouring MET exon 14 skipping alteration ( METex14).Objective:To analyse post hoc, the association between circulating tumour DNA (ctDNA) biomarkers and clinical outcomes, including resistance, with savolitinib.Design:A multicentre, single-arm, open-label phase 2 study.Methods:All enrolled patients with baseline plasma samples were included. Outcomes were objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) by baseline METex14 and post-treatment clearance, coexisting gene alterations at baseline and disease progression.Results:Among 66 patients with baseline ctDNA sequencing, 46 (70%) had detectable METex14. Frequent coexisting baseline gene alterations included TP53 and POT1 mutations. Patients with detectable baseline METex14 exhibited worse PFS [hazard ratio (HR), 1.77; 95% confidence interval (CI), 0.88–3.57; p = 0.108] and OS (HR, 3.26; 95% CI, 1.35–7.89; p = 0.006) than those without, despite showing a numerically higher ORR. Among 24 patients with baseline detectable METex14 and evaluable postbaseline samples, 13 achieved METex14 clearance post-treatment. Median time to first clearance was 1.3 months (range, 0.7–1.5). METex14 post-treatment clearance was associated with better ORR (92.3%; 95% CI, 64.0–99.8 versus 36.4%; 95% CI, 10.9–69.2; p = 0.0078), PFS (HR, 0.44; 95% CI, 0.2–1.3; p = 0.1225) and OS (HR, 0.31; 95% CI, 0.1–1.0; p = 0.0397) versus non-clearance. Among 22 patients with disease progression, 10 acquired pathway alterations (e.g. in RAS/RAF and PI3K/PTEN) alone or with secondary MET mutations (D1228H/N and Y1230C/H/S).Conclusion:ctDNA biomarkers may allow for longitudinal monitoring of clinical outcomes with savolitinib in patients with METex14-positive PSC and other NSCLC subtypes. Specifically, undetectable baseline METex14 or post-treatment clearance may predict favourable clinical outcomes, while secondary MET mutations and other acquired gene alterations may explain resistance to savolitinib.Registration:The trial was registered with ClinicalTrials.gov (NCT02897479) on 13 September 2016.